Obesity: Metabolic and Clinical Consequences

Return to The Medical Biochemistry Page

© 1996–2017 themedicalbiochemistrypage.org, LLC | info @ themedicalbiochemistrypage.org

What is Obesity?












Obesity is defined as a physical condition in which an individual has a body mass index (BMI) ≥30kg/m2. The BMI is a measure of the relationship between an individuals weight and height. The BMI is calculated by dividing a persons weight in kilograms by the square of their height in meters. The medical utility for determining a persons BMI is that this measure describes the body weight relative to height and it thus, strongly correlates with the total body fat content in adults. It is important to note that in certain individuals, such as body builders who have large muscle mass, a high BMI does not correlate with high fat content. Given that most Americans measure their weight in pounds and their height in inches the following Table can be used to approximate ones weight from their BMI and their height in inches or their BMI from their approximate weight and their height in inches.

19 20 21 22 23 24 25 26 27 28 29 30 35 40
Weight (lb)
58 91 96 100 105 110 115 119 124 129 134 138 143 167 191
59 94 99 104 109 114 119 124 128 133 138 143 148 173 198
60 97 102 107 112 118 123 128 133 138 143 148 153 179 204
61 100 106 111 116 122 127 132 137 143 148 153 158 185 211
62 104 109 115 120 126 131 136 142 147 153 158 164 191 218
63 107 113 118 124 130 135 141 146 152 158 163 169 197 225
64 110 116 122 128 134 140 145 151 157 163 169 174 204 232
65 114 120 126 132 138 144 150 156 162 168 174 180 210 240
66 118 124 130 136 142 148 155 161 167 173 179 186 216 247
67 121 127 134 140 146 153 159 166 172 178 185 191 223 255
68 125 131 138 144 151 158 164 171 177 184 190 197 230 262
69 128 135 142 149 155 162 169 176 182 189 196 203 236 270
70 132 139 146 153 160 167 174 181 188 195 202 207 243 278
71 136 143 150 157 165 172 179 186 193 200 208 215 250 286
72 140 147 154 162 169 177 184 191 199 206 213 221 258 294
73 144 151 159 166 174 182 189 197 204 212 219 227 265 302
74 148 155 163 171 179 186 194 202 210 218 225 233 272 311
75 152 160 168 176 184 192 200 208 216 224 232 240 279 319
76 156 164 172 180 189 197 205 213 221 230 238 246 287 328

Obesity is approaching epidemic proportions in the US and many other industrialized countries. In the US the prevalence of obesity now exceeds 30% of the population and represents the highest rate of obesity worldwide. Since 1980 the prevalence of obesity in adults in the US has increased 2-fold. However, much more disturbing is the fact that in this same time period the rate of childhood and adolescent obesity increased 3-fold. The Table below associates a given BMI range with the risk for cardiovascular disease and atherosclerosis.

BMI Category Waist less than or equal to 40 in. (men) or 35 in. (women) Waist greater than 40 in. (men) or 35 in. (women)
18.5 or less underweight N/A N/A
18.5 - 24.9 normal N/A N/A
25.0 - 29.9 overweight increased risk high risk
30.0 - 34.9 obese high risk very high risk
35.0 - 39.9 obese very high risk very high risk
40 or greater extremely obese extremely high risk extremely high risk

Obesity is associated with several serious and life threatening complications resulting in significant increases in morbidity and mortality relative to lean individuals. These complications include insulin resistance (IR), type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), atherosclerosis, degenerative disorders such as dementia, and also in many instances cancers. The combination of abdominal obesity, hyperlipidemia, IR, pro-inflammatory status, and hypertension is clinically referred to as the Metabolic Syndrome. Many of these conditions are discussed in this page and elsewhere in this site.

back to the top

Obesity and Development of the Metabolic Syndrome

A little more than 20 years ago Dr. Gerald M. Reaven put forth the concept that the insulin resistance syndrome was the root cause of glucose intolerance, elevated LDL along with reduced HDL, and hypertension. This clinical concept has evolved into what is now referred to as the metabolic syndrome. The metabolic syndrome, MetS (also once referred to as Syndrome X), is a disorder that defines a combination of metabolic and cardiovascular risk determinants. These risk factors include insulin resistance, hyperinsulinemia, central adiposity (obesity associated with excess fat deposits around the waist), dyslipidemia, glucose intolerance, hypertension, pro-inflammatory status, and microalbuminemia. The hallmark feature of MetS is indeed insulin resistance. Several other clinical abnormalities have recently been associated with MetS including non-alcoholic fatty liver disease (NAFLD), atherosclerosis, oxidative stress, and polycystic ovary syndrome (PCOS). Although obesity, ectopic fat accumulation, and an inflammatory status are central to the pathology of MetS, not all obese individuals develop MetS and not all individuals with MetS are obese. These observations indicate that MetS has a multi-factorial etiology that involves a series of complex interactions between a particular individuals dietary habits, hormonal status, and genetic background. Increasing evidence indicates that the risk of MetS can be developmentally induced. Epidemiological studies in humans and animal models of MetS demonstrate an association between poor nutrition during fetal development and an increased risk of adult cardiovascular disease.

Given the complexities of the factors contributing to the metabolic syndrome numerous health groups in various countries have defined the disorder with slightly different criteria. Some health organizations believe that insulin resistance is the signal most important predictor for future development of type 2 diabetes and cardiovascular disease that the disorder is defined as the insulin resistance syndrome. In addition, there are significant differences in ethnic predisposition to the effects of the dysfunctions of the metabolic syndrome that some criteria must be assessed with this in mind. Of particular note is the use of waist circumference as an indicator of obesity. The following Table lists the criteria set forth by the American Heart Association and the National Heart, Lung and Blood Institute as defining the metabolic syndrome.

Defining Criteria Parameters of Criteria
elevated fasting blood glucose ≥ 100 mg/dL (≥ 5.6mmol/L)
elevated waist circumference ≥ 102 cm (≥ 40 inches) in men
≥ 88cm (≥ 35 inches) in women
elevated triglycerides ≥ 150mg/dL (≥ 1.7mmol/L)
reduced HDL cholesterol (HDLc) < 40mg/dL (< 1.03mmol/L) in men
< 50mg/dL (< 1.3mmol/L) in women
elevated blood pressure ≥ 130mm Hg systolic
≥ 85mm Hg diastolic

Although MetS is not exclusively associated with type 2 diabetes and the associated insulin resistance, the increasing prevalence of obesity and associated development of type 2 diabetes places insulin resistance as a major contributor to the syndrome. The metabolic syndrome is defined as a clustering of atherosclerotic cardiovascular disease risk factors that include visceral adiposity (obesity), insulin resistance, low levels of HDLs and a systemic proinflammatory state. There are key components to the metabolic syndrome which include in addition to insulin resistance (the hallmark feature of the syndrome), hypertension, dyslipidemia, chronic inflammation, impaired fibrinolysis, procoagulation and most telling central obesity.

The role of adipose tissue (fat) stems from the fact that the organ is active at secretion of cytokines, termed adipocytokines. These include tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), leptin, adiponectin and resistin. Leptin has received particular attention of late due to its role in obesity in addition to the fact that recent data indicates that plasma leptin levels are found to be predictive of the potential for cardiovascular pathology.

Many clinicians and researchers believe that insulin resistance underlies the cardiovascular pathologies of the metabolic syndrome. One primary reason for this is the role of insulin in fat homeostasis. As indicated above, the major role of insulin is to induce the storage of fuel. This can be as fat (triacylglycerides, TGs) in adipose tissue or as carbohydrate in the form of glycogen in liver and skeletal muscle. The effect of insulin resistance at the level of fat homeostasis is an increase in circulating TGs, referred to as dyslipidemia. Due to insulin resistance there is an increase in the delivery of peripheral fatty acids to the liver which in turn drives hepatic TG synthesis. These TGs are then packaged into lipoprotein particles termed VLDLs (very low density lipoproteins) which are returned to the circulation.

An additional role of insulin resistance in the overall cardiac pathology associated with the metabolic syndrome relates to the normal role of insulin in platelet function. In platelets, insulin action leads to an increase in endothelial nitric oxide synthase (eNOS) activity that is due to its phosphorylation by AMPK. Activation of NO production in platelets leads to a decrease in thrombin-induced aggregation, thereby, limiting the pro-coagulant effects of platelet activation. This response of platelets to insulin function clearly indicates why disruption in insulin action is a major contributing factor in the development of the metabolic syndrome.

Taken together, the insulin resistance and its associated negative effects on metabolism, the increased levels of circulating TGs, the reduced levels of HDLs and hypertension, all contribute to the progression of atherosclerosis. With associated coagulation and fibrinolysis pathologies, the cardiovascular events of the metabolic syndrome can be devastating.

Although, as indicated above, there are many examples of individuals who are obese but do not manifest MetS there is still a very strong correlation between obesity and increased risk for development of MetS. In addition, the incidence of MetS increases with the severity of obesity. It has been observed that over 50% of obese adolescents go on to develop MetS. Also, given the high correlation between MetS and insulin resistance it is not at all surprising that there is a strong link between obesity and MetS. Insulin resistance (identified as type 2 diabetes) is 5 to 6 times more common in individuals with a body mass index (BMI) >30kg/m2 than in individuals of normal weight.

Although the precise mechanism(s) by which obesity leads to the development of MetS is not fully understood, there are many overlapping pathways of metabolism that are disrupted in obesity that can be identified as important in the progression to MetS. Not the least of which is the role that obesity, in particular visceral obesity, plays in the progression to insulin resistance. Recall that as mentioned above, insulin resistance is the hallmark manifestation of MetS.

Since many of these pathologies can be reversed with proper diet and exercise, it is in a persons best interest to take responsibility for the role their life style choices play in the development of the metabolic syndrome.

back to the top

Genetic Factors in Metabolic Syndrome

Numerous epidemiological studies have implicated developmental origins in the progression to the metabolic syndrome. There appears to be a clear correlation between poor nutritional status of the mother during fetal development and the potential for increased risk for MetS to her child in later life. These correlations have also been observed in animal studies where prenatal diets in mothers impacts their offspring. Overfeeding during of the mother during fetal development as well as excessive nutritional intake by the mother during the pre-weaning period of postnatal development results in increased obesity, adipocyte hypertrophy, reduced activity, insulin resistance, elevated blood pressure, endothelial cell dysfunction, and altered cardiovascular and renal function in offspring. When mothers are obese and fed high-fat diets during fetal development their adult offspring exhibit impaired glucose tolerance, hyperinsulinemia, dyslipidemia, hypertension, resistance to the anorexic actions of the leptin on the hypothalamus, and develop NAFLD. Additional evidence indicates that manipulation of fetal protein access leads to modified pancreatic islet cell expansion resulting in reduced pancreatic β-cell mass and persistent deficits in glucose homeostasis.

There is now a clear link between maternal dietary status and future development of MetS in adult offspring. Likewise, because the risks of metabolic syndrome in the general population, due to identified inherited polymorphisms is relatively small, the huge increase in the numbers of individuals with the disorder is most likely due to epigenetic changes that occur during early fetal development. The role of epigenetics in transgenerational disease manifestation has been outlined in several studies on the outcomes of children born to parents who experienced famine while pregnant. These children are far more likely to develop diabetes, obesity, and cardiovascular disease than children from parents of similar backgrounds who were not nutritionally deprived. Of striking significance is that the second generation children (grandchildren of the starved mothers) were more likely to be born with low birth weight regardless of the nutritional status of their mothers. The potential for diet and nutrition to effect epigenetic changes in offspring on multiple generations has been conclusively demonstrated in animal models. In mice, the lack of adequate fetal nutrition results in a reduction in the methylation status of the promoter regions of several transcriptional regulators. Hypomethylation of genes is most often associated with increased transcriptional activation. One transcriptional regulator of key metabolic significance whose promoter has been found to be hypomethylated in offspring of nutritionally deprived mothers is PPARα. PPARα is highly expressed in the liver, skeletal muscle, heart, and kidney. Its function in the liver is to induce hepatic peroxisomal fatty acid oxidation during periods of fasting. Expression of PPARα is also seen in macrophage foam cells and vascular endothelium. Its role in these cells is thought to be the activation of anti-inflammatory and anti-atherogenic effects. For a detailed discussion of the PPAR family of transcriptional regulators visit the PPAR page.

back to the top

Hypothalamic Control of Appetite

The hypothalamus is located below the thalamus and just above the brain stem and is composed of several domains (nuclei) that perform a variety of functions. The hypothalamus forms the ventral portion of the region of the brain called the diencephalon. Anatomically the hypothalamus is divided into three broad domains termed the posterior, tuberal, and anterior regions. Each of these three regions is further subdivided into medial and lateral areas. The various nuclei of the hypothalamus constitute the functional domains of the various hypothalamic areas. The primary nuclei of the hypothalamus that are involved in feeding behaviors and satiety (the sensation of being full) include the arcuate nucleus of the hypothalamus (ARC, also abbreviated ARH), the dorsomedial hypothalamic nucleus (DMH or DMN), and the ventromedial hypothalamic nucleus (VMH or VMN) all of which are located in the tuberal medial area. The ARC is involved in control of feeding behavior as well as secretion of various pituitary releasing hormones, the DMH is involved in stimulating gastrointestinal activity, and the VMH is involved in satiety. Early experiments involving lesions in the hypothalamus demonstrated that the lateral hypothalamic area (LHA) is responsible for transmitting orexigenic signals (desire for food intake) and loss of this region results in starvation. The medial hypothalamic nuclei (VMH and to a lesser extent the DMH) are responsible for the sensations of satiety and lesions in these regions of the hypothalamus result in hyperphagia (excessive hunger) and obesity.

Appetite is a complex process that results from the integration of multiple signals at the hypothalamus. The hypothalamus receives neural signals, hormonal signals such as leptin, cholecystokinin (CCK) and ghrelin and nutrient signals such as glucose, free fatty acids, amino acids and volatile fatty acids. This effect is processed by a specific sequence of neurotransmitters beginning within the ARC and orexigenic cells containing neuropeptide Y (NPY) and Agouti-related peptide (AgRP) responsive neurons and anorexigenic cells containing pro-opiomelanocortin (POMC) (yielding the neurotransmitter α-MSH) and cocaine and amphetamine-regulated transcript (CART) responsive neurons. These so called first order neurons act on second order orexigenic neurons (containing either melanin concentrating hormone, MCH or orexin) or act on anorexigenic neurons (expressing corticotropin releasing hormone, CRH) to alter feed intake. In addition, satiety signals from the liver and gastrointestinal tract signal through the vagus nerve to the nucleus of the solitary tract (NTS, for the latin term nucleus tractus solitarii) to cause meal termination, and in combination with the hypothalamus, integrate the various signals to determine the feeding response. The activities of these neuronal pathways are also influenced by numerous factors such as nutrients, fasting and disease to modify appetite and hence impact on growth and reproduction.

Hypothalamic circuits in the control of appetite

Hormonal circuits from the gut (stomach, small intestine, and pancreas) and fat (adipose tissue) that impact the sensations of hunger and satiety that are exerted via hypothalamic neuroendocrine pathways. Ghrelin from the stomach, leptin from adipose tissue, insulin from the pancreas, and peptide tyrosine tyrosine (PYY) from the small intestine bind to receptors on orexigenic and/or anorexigenic neurons in the ARC of the hypothalamus. The effects of these peptide hormone-receptor interactions are release of either the orexigenic neuropeptides NPY and AgRP or the anorexigenic neuropeptides CART and the POMC-derived peptide α-MSH. These neuropeptides from the ARC travel along axons to secondary neurons in other areas of the hypothalamus such as the paraventricular nucleus (PVN). The ultimate effects of these signaling cascades are changes in the sensation of hunger and satiety in the NTS. LEPRB is the large form of the leptin receptor (see the Adipose Tissue page for descriptions of leptin and leptin receptors). GHSR is the growth hormone secretagogue receptor to which ghrelin binds. MC3R and MC4R are melanocortin 3 receptor and melanocortin 4 receptor, respectively. Y1R and Y2R are the NPY receptors 1 and 2, respectively (see the next section below for more information on NPY receptors.)

The POMC-derived melanocortin peptides include α-MSH, β-MSH, γ-MSH, ACTH1-24, and ACTH1-13–NH2 (desacetyl-α-MSH). The POMC-derived melanocortins belong to a family of peptides referred to as the melanocortin system. This system includes the POMC-derived melanocotins which exhibit agonist activities, the antagonist peptide AgRP, the melanocortin receptors (MCR), and the melanocortin receptor accessory proteins (MRAPs). The MCR family of receptors consists of five identified members termed MC1R through MC5R.

The melanocortin system has been shown to be critical in the regulation of food intake and energy expenditure via a number of different assay systems involving both humans and animals. It is important to note that although β-MSH and γ-MSH are found to be produced in human brain they are not found in rodent brain or pituitary. However, when administered into the brain of animals the melanocortins α-MSH, β-MSH, and ACTH1-24 inhibit the intake of food. The actions of MSH peptides in feeding behavior is exerted primarily via peptide binding to the MC4R and to a lesser extent to the MC3R. Genetic mutations in humans as well as in animals that disrupt the expression and processing (this includes the proteases that process the POMC precursor) of POMC peptides and MCRs are associated with changes in energy balance and can lead to obesity and type 2 diabetes. In humans there have been mutations identified in prohormone convertase 1/3 (PC1/3) and carboxypeptidase E (CPE), as well as in the α-MSH degrading enzyme prolylcarboxypeptidase (PRCP) that are associated with energy imbalance and a propensity for obesity. In mice a mutation in the CPE gene also results in the development of late-onset obesity. In genome-wide screens for gene polymorphisms associated with an increased risk of developing type 2 diabetes the MC4R gene was identified. Mutations in the MC4R gene are the most frequent causes of severe obesity in humans.

In mice ablation of the POMC gene (POMC-null) results in viable animals, even though they have minimal adrenal tissue and undetectable glucocorticoids due to the lack of ACTH. These animals develop obesity but do not become diabetic. Although not diabetic these mice do have a disruption in the regulation of glucagon secretion in response to experimental hypoglycemia. This indicates that POMC-derived peptides are involved in the regulation of glucagon. In humans a rare POMC-null mutation has been described. Unlike the situation in the POMC-null mice, humans with a lack of POMC expression are unable to survive without glucocorticoid supplementation from birth. Individuals that survive have red hair, dramatically increased desire for food intake, and high propensity for obesity. These conditions are the same as those seen in POMC-null mice. Another POMC mutation that has been identified in humans resulting in obesity is a point mutation in the cleavage site between β-MSH and β-endorphin. The consequences of this mutation suggests that β-MSH may be a significant endogenous anorectic agonist that activates the MC4R.

Neuropeptide Y, NPY

NPY is a hypothalamic neuroendocrine protein that is a member of a family of structurally related proteins identified as the pancreatic polypeptide (PP) family of hormones. In addition to NPY this family is composed of two gut hormones, pancreatic polypeptide (PP) and peptide tyrosine-tyrosine (PYY) both of which are discussed below. Each of these peptide hormones contains 36 amino acids consisting of numerous tyrosines (hence the Y peptides nomenclature) and an α-amidation at the C-terminus. The three-dimensional structure of these hormones includes a hairpin-like motif referred to as the pancreatic polypeptide fold (PP-fold). The PP-fold is required for interaction of the hormones with specific G-protein coupled receptors (GPCRs).

The PP family of proteins bind to a family of receptors that were originally characterized as NPY receptors. There are four NPY receptors in humans and they are designated as Y1, Y2, Y4, and Y5. An additional receptor identified as Y6 is found in mice and rabbits. Comparisons of the amino acid sequences of the four human Y receptors show that receptors Y1, Y4 are more closely related to each other than to the receptors Y2 and Y5. Receptors Y1, Y2, and Y5 preferentially bind NPY and PYY, whereas, Y4 exhibits highest affinity for PP. Although the Y5 receptor is expressed and binds ligand it is a truncated protein. The Y2 receptor is involved in anorexigenic responses (suppression of appetite) whereas the Y1 and Y5 receptors have been shown to induce orexigenic responses (stimulation of appetite). The Y2 receptors thus referred to as inhibitory receptors with respect to the activity of NPY and they are abundantly expressed on NPY neurons in the arcuate nucleus (ARC) of the hypothalamus.

NPY is expressed throughout the mammalian brain with highest levels found in the ARC of the hypothalamus. NPY is one of the most potent orexigenic factors produced by the human body. Within the ARC there are two neuronal populations that exert opposing actions on the desire for food intake. Neurons that co-express NPY and another neuropeptide called agouti-related peptide (AgRP) stimulate food intake, whereas, neurons that co-express POMC and cocaine and amphetamine-regulated transcript (CART) suppress the desire for food intake. The role of NPY in appetite control can be demonstrated by central administration of NPY which results in a markedly increased desire for food intake. The Y1 and Y5 receptors mediate the bulk of the effects of NPY on the hypothalamic-pituitary-thyroid axis. Within the ventromedial nucleus (VMN) of the hypothalamus, binding of NPY to the Y1 receptor results in inhibition of neuronal function (via hyperpolarization) which results in interference with the satiety role of the VMN. The majority of hypothalamic Y2 receptors are found on NPY-containing neurons. Conversely, Y2 receptor activation in the ARC results in inhibition of the actions of NPY which accounts for the anorexigenic actions associated with Y2 activation.

Of significance to dieting and weight loss is the fact that when people lose excess weight the level of NPY increases which likely is a contributing factor to the inability of most people to keep the weight off. This phenomenon has been demonstrated in mice fed a high-fat diet. These mice will become obese, have increased fat mass, and increased circulating levels of leptin. When the animals are placed on a calorie-restricted diet they lose the excess fat and leptin levels decline. However, the level of expression of the NPY gene is observed to be significantly increased. This and other data indicate that NPY is also one of the most important hypothalamic-derived neuropeptides mediating the effects of leptin on overall energy homeostasis. Whereas, losing excess weight is associated with increased expression of NPY, the levels of the anorexigenic peptides, POMC and CART, do not change.

Protein Tyrosine Tyrosine, PYY

PYY produced by and is secreted from intestinal enteroendocrine L-cells of the ileum and colon. Additional gut hormones that are secreted along with PYY include GLP-1 and oxyntomodulin (OXM). Both of these latter gut hormones are discussed above. Secreted forms of PYY include PYY1-36 and PYY3-36 with PYY3-36 being generated via the actions of dipetidylpeptidase IV (DPP-4 or DPP-IV). DPP-4 is the same enzyme that inactivates GLP-1. Within the gastrointestinal tract the highest detectable levels PYY are found in the rectum with low levels found in the duodenum and jejunum. Within the central nervous system (CNS) PYY is detectable in the hypothalamus, medulla, pons, and spinal cord.

The release of PYY results in reduced gut motility, a delay in gastric emptying, and an inhibition of gallbladder contraction. All of these actions are, like that of PP, associated with the ileal brake. Given that PYY is secreted from cells of the distal gut there must be signals associated with the response of the proximal gut to food intake that lead to PYY release. Indeed humoral factors such as CCK and gastrin are thought to mediate the rapid release of PYY in response to eating. The amount of PYY released in response to the ingestion of food is proportional to the caloric intake. Animal and human studies of anorectic conditions indicate that PYY has a critical role in satiety. Within the CNS, PYY exerts its effects on satiety via actions in the hypothalamus, specifically the ARC of the hypothalamus. The ARC is in close proximity to the deficient blood-brain barrier of the median eminence of the hypothalamus, thus allowing this region to respond rapidly to the release of a gut hormone into the circulation. Evidence confirming the role of PYY in inducing anorexia has been obtained in mice by direct injection of the peptide into the ARC. Given the role of PYY in appetite suppression it is thought that disturbances in PYY release in response to food intake may play a role in the development of obesity. Indeed, in obese humans there is a blunted PYY response following food intake compared to lean humans. Current therapeutic interventions designed to combat obesity involve studies of the efficacy of PYY at suppressing appetite.

Oxyntomodulin, OXM

Oxyntomodulin (OXM) is so called given that is was originally discovered from work examining the inhibition of the activity of oxyntic glands (gastric acid secreting) of the stomach. OXM is a 37 amino acid peptide derived from the pre-pro-glucagon gene and contains the entire 29 amino acids of the pancreas-derived glucose regulating hormone glucagon. The OXM protein contains an additional 8 amino acids at its C-terminus relative to glucagon. Synthesis and release of OXM occurs in the enteroendocrine L cells of the distal gut. These are the same cell populations that secrete GLP-1 and PYY. The secretion of OXM occurs within 5-10 minutes following ingestion of food and peaks within 30 minutes. The amount of OXM that is released is directly proportional to caloric intake. In addition to stimulated release in response to food intake, OXM exhibits diurnal variation in its concentration in the blood with highest levels detected in the evening and lowest levels in the morning.

Thus far there has been no specific OXM receptor identified. Evidence suggests that the anorexigenic effects of OXM are in fact exerted via the GLP-1 receptor (GLP-1R). In mice in which the GLP-1R gene has been knocked out the anorectic responses to injected OXM are abolished. Like GLP-1, OXM has demonstrated incretin activity (incretins stimulate insulin release in response to food intake) and this activity is abolished in the GLP-1R knock-out mouse. In addition, OXM exerts a protective effect on pancreatic β-cells similar to that exerted by GLP-1. Although the affinity of OXM for the GLP-1R is at least 50 fold less than that of GLP-1 itself, the ability of OXM to exert inhibition of food intake is equal to that of GLP-1. With respect to effects on food intake exerted via the hypothalamus when either OXM or GLP-1 are administered peripherally they exert differential neuronal activation within the hypothalamus. This suggests that these two hormones act via different hypothalamic pathways involved in appetite control. When OXM is administered into the brain the response is suppression of the effects of circulating ghrelin. These results suggest that part of the appetite suppressing effects of OXM are mediated by reduced ghrelin as well as increased hypothalamic release of anorexigenic peptides.

Of potential significance to the treatment of obesity, when OXM is administered intravenously to human subjects there is an observed reduction (19.3%) in food intake at mealtime. Additionally significant is the fact that this reduction in desire for food intake persisted over the course of 12 hours. When OXM is administered subcutaneously to overweight and obese subjects over a period of 4 weeks there is a significant reduction in body weight. The average weight loss in the volunteers was 2.3kg (1 lb) compared to only 0.5kg in untreated control subjects. The weight loss observed in these studies was likely due to a combination of reduced desire for food intake as well as an increased metabolic expenditure. When OXM was administered over a 4 day period to human subjects there was an observed 10% increase in total energy expenditure. Although these results prove promising for the potential for OXM in the treatment of obesity it is important to note that OXM is a target for inactivation by DPP-4 just as is GLP-1. Therefore, any OXM agonist must be resistant to inactivation by DPP-4.

Cholecystokinin, CCK

Cholecystokinin (CCK) is derived via post-translational modification of the pro-cholecystokinin gene product. CCK was the first gut hormone to be identified as having an effect on appetite. There are several bioactive forms of CCK that are designated based upon the number of amino acids in the peptide. The four major forms are CCK-8, CCK-22, CCK-33, and CCK-58. The predominant form that is found in human plasma is the CCK-33 form. The CCK isoforms are also found as sulfated and non-sulfated variants. CCK is secreted from intestinal enteroendocrine I cells predominantly in the duodenum and jejunum. The level of CCK in the blood rises within 15 minutes of food ingestion and reaches a peak by 25 minutes. The elevation in plasma CCK levels remains for approximately 3 hours following a meal. The most potent substances initiating a release of CCK from the I cells are fats and proteins. Conversely duodenal bile acids are potent suppressors of the secretion of CCK.

CCK exerts its biological actions by binding to specific G-protein coupled receptors (GPCRs). There are two CCK receptor types identified as CCK-1 and CCK-2. The CCK receptors are also identified as CCKA and CCK whose designations referred to their location of prominent expression with CCKA referring to the alimentary tract (the gut) and CCKB referring to the brain. However, both receptors are found widely expressed in the CNS as well as the periphery.

Upon binding its receptors in the gut CCK induces contractions of the gallbladder and release of pancreatic enzymes and also inhibits gastric emptying. Within the brain (specifically the median eminence and ventromedial nucleus of the hypothalamus, VMH) CCK actions elicit behavioral responses and satiation. The CCK-1 receptor is believed to be the receptor primarily responsible for alterations in feeding behavior. Evidence for this comes from the Otsuka Long Evans Tokushima Fatty rat which has a null mutation in the CCK-1 receptor. These rats are hyperphagic and develop obesity even on a fat restricted diet. The situation is not entirely conclusive since knock-out of the CCK-1 receptor in mice does not result in a similar phenotype. However, the ability of CCK to regulate food intake has been clearly demonstrated in numerous studies. For example central administration of CCK results in reduced food intake. Of significance to appetite control, this effect is enhanced with co-administration of leptin. The synergistic effects of CCK and leptin may be due to the fact that their receptors are co-localized to the same sensory vagal afferent neurons.

In humans the correlations between CCK and obesity are growing. Studies have shown that the fasting levels of CCK are lower in morbidly obese individuals than in lean individuals. In addition, the post-feeding responses to CCK in morbidly obese individuals in attenuated compared to lean individuals. The primary appetite suppressing effects of CCK are exerted via its inhibitory actions on NPY neurons (orexigenic neurons) in the DMH and the NTS.

Using genome wide screens for polymorphisms in genes associated with obesity and/or increased feeding behaviors have shown a correlation to the CCK_H3 haplotype. Polymorphisms in the CCK-1 receptor gene may also predispose an individual to obesity. Although CCK is known to be involved in satiation it may have limited use as a therapeutic for the treatment of obesity at least when used alone. This is due to the fact that when studied in laboratory animals administration of CCK resulted in reduced meal size but the animals increased their frequency of food intake such that the overall outcome was no net change in body weight. However, given the synergistic actions of CCK and leptin combination therapies of these two hormones may prove useful.

back to the top

Obesity and Cardiovascular Disease

Obesity is directly correlated to increased morbidity resulting primarily from hypertension and cardiovascular disease. However, since obesity is highly correlated to the development of type 2 diabetes, the pathophysiological complications associated with diabetes also contributes to obesity related mortality. Obesity is the result of excess accumulation of body fat including both cutaneous and visceral adipose tissue. As adipose tissue enlarges due to excess triglyceride accumulation physiological changes occur that result in increased inflammatory responses in the tissue. In addition to increased pro-inflammatory events in adipose tissue in response to excess lipid accumulation, so too do these same disruption occur in the liver. One consequence of the enhanced inflammatory status of the liver and adipose tissue in obesity is an associated insulin resistance (IR). For more information on the effects of obesity-induced IR in the liver see the section below and also see the discussion of IR in the Insulin Functions page.

Insulin resistance induced by obesity is a major factor in the development of cardiovascular disease in obese individuals. Within the vasculature insulin exerts vasodilator action as a result of increased nitric oxide (NO) production. This function of insulin is an important component of the ability of the hormone to enhance glucose uptake by skeletal muscle. The insulin-mediated signaling pathway that triggers production of NO in vascular endothelium involves the same signaling proteins (PI3K, PKD, and AKT/PKB) that are components of metabolic regulatory pathways induced by insulin. Inactivation of endothelial cell NO production, as occurs due to IR, results in endothelial dysfunction and promotes the development of atherosclerosis.

Atherosclerosis is in essence a pro-inflammatory condition where there is enhanced leukocyte infiltration into the vascular endothelium and an associated increase in secretion of pro-inflammatory cytokines which sets up a feed-forward process that builds upon itself. One of the principal pro-inflammatory cytokines whose expression is increased in obesity, and plays a critical role in the development of atherosclerosis, is tumor necrosis factor-α (TNF-α). Expanding adipose tissue secrete ever increasing amounts of TNF-α as well as other proatherogenic factors such as plasminogen activator inhibitor type 1 (PAI-1). Increased circulating TNF-α results in enhanced adhesion of leukocytes to the endothelium. Adherent monocytes infiltrate the endothelial layer of the vasculature where they phagocytose the excess lipoprotein particles in the vasculature and become foam cells. Foam cell secretion of cytokines activates the underlying smooth muscle cells (SMCs) to proliferate and migrate. As SMCs proliferate they increase production of extracellular matrix which leads to decreased fluidity ("hardening") of the vasculature. The increased levels of PAI-1 inhibit the ability of plasminogen to be converted to plasmin which is required to dissolve fibrin clots that will be generated as a result of the local inflammatory processes. As the disease progresses atherosclerotic plaque formation occurs and expands. Plaques can become large enough to result in vessel occlusion or to the release of a fibrous clot which can travel to the heart of lungs leading to fatal embolisms.

back to the top

Non-Alcoholic Fatty Liver disease: NAFLD

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the Western world. NAFLD is characterized by fatty infiltration of the liver in the absence of alcohol consumption. For information on the role of alcohol consumption and the formation of the fatty liver syndrome visit the Ethanol Metabolism page. The mildest forms of NAFLD consists of simple steatosis (abnormal retention of lipids inside cells) and can progress to non-alcoholic steatohepatitis (NASH) which represents a deleterious hepatic inflammatory disorder characterized by advanced liver fibrosis and cirrhosis which ultimately can result in hepatocellular carcinoma and death. In the clinical environment NAFLD is believed to account for as much as 90% of all cases of elevated liver function test enzymes in patients who do not manifest with identifiable causes of hepatic disease (e.g. viral hepatitis).

The abnormal deposition of fat in the liver in NAFLD comprises a complex pathophysiology. However, what is known about the process is that there is increased visceral adiposity plus insulin resistance with increased free fatty acids (FFAs) being released from adipose tissue. As there is a large increase in visceral adipose tissue in obese individuals this contribution of adipose tissue derived FFAs is significant to the development of NAFLD. These conditions set the stage for the onset and perpetuation of the steatosis in the liver. Additional pathophysiology includes an enhanced state of hepatic oxidative stress and lipid peroxidation, decreased antioxidant defenses, early mitochondrial dysfunction, and iron accumulation. Associated with these abnormal hepatic processes are an imbalance in the secretion of adipokines and a chronic pro-inflammatory status. In addition, gut-derived microbial adducts participate in the propagation of the hepatic dysfunction (see section below on role of gut bacteria in obesity).

One of the most significant contributing factors to the development of NAFLD is insulin resistance in the liver. For more information on the causes of insulin resistance visit the Insulin Functions page. Insulin resistance (IR) in the liver is associated with increased hepatic glucose output since the insulin-suppressing effects on gluconeogenesis are impaired. The increased hepatic glucose output exacerbates the hyperglycemia that is present in obesity and contributes to the IR in the periphery ultimately resulting in progression to type 2 diabetes. Peripheral IR at the level of adipose tissue and skeletal muscle results in increased circulating FFAs which make their way to the liver. In addition, the hepatic IR results in increased hepatic fatty acid synthesis which then, in conjunction with the circulating FFAs, serves as the precursors for increased triglyceride accumulation in the liver.

Hepatic IR is induced by the excess accumulation of FFAs. Within the hepatocyte metabolites of the FFA re-esterification process, including long-chain acyl-CoAs and diacylglycerol (DAG), accumulate. Excess FFAs also participate in the relocation of several protein kinase C (PKC) isoforms, from the cytosol to the membrane compartment. These PKC isoforms include PKC-β2, PKC-δ, and PKC-theta (PKC-θ). DAG is a potent activator of these PKC isoforms and the membrane-associated PKC will phosphorylate the intracellular portion of the insulin receptor on serine residues which results in impairment of insulin receptor interaction with downstream signaling proteins including insulin receptor substrate 1 (IRS1) and IRS2. Loss of IRS1 and IRS2 interaction with the receptor prevents interaction with phosphatidylinositol 3-kinase (PI3K) and its' subsequent activation. For more information on insulin receptor signaling pathways visit the Insulin Functions page. In addition to serine phosphorylation of the insulin receptor, various PKCs have been shown to phosphorylate IRS1 and IRS2 further impairing the ability of these insulin receptor substrates to associate with the insulin receptor.

The FFA-induced down-regulation of insulin signaling pathways results in activation of several kinases involved in stress responses. These kinases include Jun N-terminal kinase (JNK), inhibitor of nuclear factor kappa B kinase beta (IKKβ), and suppressors of cytokine signaling-3 (SOCS-3). Like PKC, JNK activity is also regulated by FFAs and is an important regulator of IR. The target of JNK action is the Ser307 of IRS-1 and this phosphorylation plays an important role in the progression to hepatic IR. Activation of IKKβ (which is required for the activation of nuclear factor kappa B, NFκB) may have the most pronounced effect on inflammatory responses in the lever. NFκB is the most important transcription factor activating the expression of numerous pro-inflammatory cytokine genes such as interleukin-1 (IL-1), IL-6, and TNF-α each of which have been shown to be involved in promoting IR. NFκB-dependent inflammatory mediators produced in hepatocytes act to reduce insulin sensitivity and to promote liver injury.

The loss of insulin-mediated repression of hepatic gluconeogenesis (leading to increased hepatic glucose output) is due to the inability of the transcription factor, forkhead box-containing protein O subfamily-1 (FOXO1), from being taken up by the nucleus. FOXO1 regulates the expression of the catalytic subunit of glucose-6-phosphatase (G6PC) and phosphoenolpyruvate carboxykinase (PEPCK). The activation of these gluconeogensis genes by FOXO1 requires an association with peroxisome proliferator-activated receptor-gamma co-activator 1 alpha (PGC-1α) and possibly also with CAAAT/enhancer-binding protein-alpha (C/EBPα). Normally the expression of C/EBPα is down-regulated by insulin via induction of the inhibitory isoform of liver-enriched transcriptional inhibitory protein.

Altered lipogenesis that occurs in the presence of hepatic and peripheral IR also contribute to the development of NAFLD. The primary regulators of hepatic lipogenesis include sterol regulated element-binding protein-1c (SREBP-1c), carbohydrate response element-binding protein (ChREBP), and peroxisome proliferator-activated receptor-gamma (PPARγ). As indicated above, hepatic IR results in increased expression of SOCS-3 which in turn results in a significant upregulation of SREBP-1c expression. The increased SREBP-1c levels activates acetyl-CoA carboxylase-2 (ACC2) which is the isoform of ACC that produces malonyl-CoA at the mitochondrial membrane. The increase in malonyl-CoA at the mitochondrial membrane causes an inhibition of carnitine palmitoyl transferase-1 (CPT-1) which transports fatty acids into the mitochondria for oxidation. Thus, inhibited CPT-1 results in decreased oxidation of fatty acids further increasing the pool of FFAs in the hepatocyte. Increased activity of SREBP-1c results in increased expression of PPARγ due to the production of an activating ligand for this transcription factor. Genes regulated by PPARγ that are involved in lipid metabolism or glucose homeostasis include lipoprotein lipase (LPL), acyl-CoA synthase (ACS), acetyl-CoA acetyltransferase (ACAT), several phospholipase A (PLA) genes, PEPCK, and glycerol-3-phosphate dehydrogenase (GPDH). The increased hepatic glucose production results in activation of ChREBP and a consequent activation of its target genes that includes ACC, fatty acid synthase (FAS) and liver-type pyruvate kinase (L-PK). The activation of these genes leads to increased de novo synthesis of fatty acids. L-PK activation results in diversion of some of the excess glucose into pyruvate and ultimately to acetyl-CoA via pyruvate dehydrogenase, and this acetyl-CoA is in excess of the ability of liver mitochondria to oxidize in the TCA cycle thus increasing the substrate pool for fatty acid synthesis. In addition, ChREBP regulates the expression of glycerol 3-phosphate acyltransferase (GPAT). GPAT is the enzyme that esterifies glycerol-3-phospate generating lysophosphatidic acid which is the first step in the synthesis of triacylglycerols (TAGs).

Whereas the development of hepatic IR is the first dysfunction contributing to the progression to NAFLD, the contribution of impaired fatty acid and complex lipid metabolism stems form the oxidative stress that is induced. Under the conditions of excess fat accumulation there is an increase in the production of reactive oxygen species (ROS) in the liver. The increased ROS production is due to a combination of mitochondrial and peroxisomal lipid oxidation. In addition mechanisms involving cytochrome P450, nicotinamide adenine dinucleotide oxidase, cyclooxygenase, and lipoxygenase participate in increased ROS production and reduced hepatic antioxidant synthesis. One mechanism resulting in reduced hepatic antioxidant production is a defect in mitochondrial uptake of glutathione (GSH). Increased hepatocyte lipid content leads to increased lipid peroxidation reactions that can result in gross morphological alterations in mitochondria and an associated impairment of electron transport. These changes result in increased TNFα expression which leads to enhanced lipid peroxidation which then exacerbates the mitochondrial dysfunction. In addition to increased TNFα production, lipid peroxidation induces the expression of other pro-inflammatory cytokines such as IL-8 and transforming growth factor-β (TGF-β). IL-8 is a chemoattractant that promotes neutrophil infiltration into the liver and TGF-β is known to promote hepatic fibrosis via induction of collagen production.

back to the top

Mitochondrial Dysfunction in Obesity and Type 2 Diabetes

Well established data demonstrate that mitochondrial dysfunction, particularly as it relates to the processes of oxidative phosphorylation (oxphos), is contributory to the development of encephalomyopathy, mitochondrial myopathy, and several age-related disorders that include neurodegenerative diseases, the metabolic syndrome, and diabetes. Indeed, with respect to diabetes, several mitochondrial diseases manifest with diabetic complications such as mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) and maternally inherited diabetes and deafness (MIDD).

Normal biogenesis of mitochondria is triggered in response to changes in the ATP/ADP ratio and to activation of AMPK which in turn results in increased expression of PPARγ co-activator 1α (PGC-1α) and nuclear respiratory factor-1 (NRF1). PGC-1α is a master transcriptional co-activator of numerous genes involved in mitochondrial biogenesis. NRF1 is a transcription factor that regulates the expression of mitochondrial transcription factor A (TFAM, for transcription factor A, mitochondrial; also designated mtTFA) which is a nuclear transcription factor essential replication, maintenance, and transcription of mitochondrial DNA. NRF1 also controls the expression of nuclear genes required for mitochondrial respiration and heme biosynthesis. Evidence has shown that both PGC-1α and NRF1 expression levels are lower in diabetic patients as as in non-diabetic subjects from families with type 2 diabetes. The expression of NRF1 is highest in skeletal muscle which is also the tissue that accounts for the largest percentage of glucose disposal in the body and, therefore, is the tissue that is most responsible for the hyperglycemia resulting from impaired insulin signaling.

Mitochondrial dysfunction results in increased production of ROS which activates stress responses leading to increased activity of MAPK and JNK. Both of these serine/threonine kinases phosphorylate IRS1 and IRS2 resulting in decreased signaling downstream of the insulin receptor. Inhibited IRS1 and IRS2 activity results in decreased activation of PI3K. PI3K activation is involved in the translocation of GLUT4 to the plasma membrane resulting in increased glucose uptake. Therefore, inhibition of PI3K results in reduced glucose uptake in skeletal muscle and adipose tissue. Mitochondrial dysfunction results in a reduction in the level of enzymes involved in β-oxidation leading to increases in intramyocellular lipid content. Indeed, skeletal muscle metabolism of lipids has been shown to be impaired in type 2 diabetics. An increased delivery of fatty acids to skeletal muscle, as well as diminished mitochondrial oxidation, results in increased intracellular content of fatty acid metabolites such as diacylglycerol (DAG), fatty acyl-CoAs, and ceramides. These metabolites of fatty acids are all known to induce the activity of protein kinase C isoforms (PKCβ and PKCδ) that phosphorylate IRS1 and IRS2 on serine residues resulting in impaired insulin signaling downstream of the insulin receptor.

Because skeletal muscle consumes the largest amount of serum glucose, mitochondrial dysfunction in this tissue will have the greatest impact on glucose disposal. However, adipose tissue also plays an important role in glucose homeostasis and mitochondrial dysfunction in this tissue has been shown to result in impaired glucose homeostasis resulting in diabetes. For example, when animals are treated with inhibitors of mitochondrial oxidation insulin-stimulated glucose uptake in adipose tissue is significantly impaired. Adipose tissue secretes a number of proteins classified as adipokines. Adiponectin is an adipokine that promotes insulin-sensitivity in insulin-responsive tissues, such as skeletal muscle. When plasma levels of adiponectin are measured in obese or type 2 diabetic subjects it is found to be significantly lower than in age and sex matched control subjects that are of normal weight or that do not have diabetes. In animal studies, the enhancement of adipocyte mitochondrial biogenesis results in increased adiponectin release from adipose tissue. Conversely, expression of adiponectin expression is decreased in adipocytes with mitochondrial dysfunction.

Given that impaired mitochondrial function is clearly associated with obesity and type 2 diabetes, it is not surprising that there is great interest in the use of pharmacology to augment mitochondrial function in the treatment of these disorders. Of significance is the fact that the thiazolidinedione (TZD) class of drugs used to treat the hyperglycemia of type 2 diabetes (see the next section) activate PPARγ which in turn increases the level of activity of PGC-1α. Although the TZDs were first marketed due to their ability to improve insulin sensitivity, they have since been shown to increase mitochondrial functions both in vitro and in vivo. Antioxidants have also been shown to enhance mitochondrial function by reducing the production of ROS. Resveratrol (found in grape skins and red wine) is a potent antioxidant whose activity is, in part, due to its ability to activate the deacetylase SIRT1 (see below). Activated SIRT1 deacetylates PGC-1α resulting in increased transcriptional activity and thus, enhanced mitochondrial biogenesis.

back to the top

Role of Gut Bacteria in Obesity

In trying to understand the epidemic of obesity much of the research has focused on two critical areas. The first is research driven by the notion that the biological and physiological interrelationships of the organ systems, primarily liver, adipose tissue, and skeletal muscle, are tightly connected and any disruption in the metabolic profile of one organ can exert a negative impact on the others. An additional avenue of more recent research is the use of modern genetic tools to scan the human genome for polymorphisms that are associated with increased risks for obesity and diabetes. However, very recently a new area of study has begun to focus on the role of the bacterial complement (microbiota) of the gut and the role these microorganisms play in altering dietary and metabolic processes.

The idea that gut bacteria can influence overall metabolism was discovered in studies using germ free mice. Mice raised in a germ free environment are resistant to diet-induced obesity. The primary mechanisms underlying this resistance are decreased absorption of glucose, decreased generation of short-chain fatty acids in the gut, reductions in hepatic lipogenesis, and alterations in adipose tissue metabolism that favors reduced triglyceride accumulation and increased fatty acid oxidation. A number of striking observations have been made in the use of animal models for studying the interaction between gut bacteria and diet-induced obesity and the development of insulin resistance and type 2 diabetes. When the guts of mice reared in a germ-free environment are colonized with bacteria from mice raised in a non-sterile environment the germ free mice amass a 60% increase in body weight and this weight gain is associated with insulin resistance. Another important observation was made when comparing the source of the bacteria to be used for gut colonization. If bacteria are used from obese mice (the ob/ob genotype) the recipient mice have a significantly greater increase in body fat mass than in recipients that were colonized with bacteria from lean mice.

The mechanism of the weight gain in these study mice was due to increased digestion of polysaccharides resulting in higher absorption and delivery of sugars to the liver. The increased carbohydrate delivery to the liver results in increased lipogenesis. When the transcriptional profiles of the livers were analyzed it was found that germ-free mice colonized with bacteria from ob/ob mice had increased levels of expression of ChREBP and SREBP-1c, both of which drive increased fatty acid synthesis via activation of the expression of ACC and FAS. Although the re-colonized mice had increased fat deposition in the liver via the described transcriptional changes, the increase in adipose tissue mass was determined to be due to increases in the activity of lipoprotein lipase (LPL). LPL is present on the surface of vascular endothelial cells and has a central role in lipoprotein metabolism.

During periods of fasting, the expression of a protein called fasting-induced adipose factor (FIAF) is stimulated by PPARα in liver and by PPARγ in white adipose tissue. FIAF is encoded by the ANGPTL4 gene (angiopoietin-like 4). FIAF inhibits adipose tissue LPL activity by acting extracellularly as an unfolding molecular chaperone. The N-terminal coiled-coil domain of FIAF transiently binds to LPL and this interaction converts LPL from a catalytically active dimer to an inactive monomer. In the re-colonized germ-free mice the level of FIAF expression was significantly reduced allowing for increased uptake of fatty acids from circulating lipoproteins and a concomitant increase in adipose tissue triglyceride storage. These changes in lipid profiles in the liver and adipose tissue of obese bacteria re-colonized rodents was correlated to changes in the composition of gut microbiota such that there was a 50% reduction in the abundance of Bacteriodetes and a proportional increase in Firmicutes.

The intestinal epithelium is the largest immunologically active organ system in the human body. This tissue provides defense of the host from invading pathogens. However, given that the microorganisms of the gut are essential for the metabolism of xenobiotic compounds, production of vitamins, degradation of non-digestible polysaccharides (involving fermentation of resistant starches and oligosaccharides), and absorption of nutrients, there is a fine interplay between the gut immune system surveillance and maintenance of the gut microbiota. The human gut contains a wide variety of microorganisms of which bacteria constitute the largest fraction. The average human gut contains some 1014 bacteria of which anaerobic bacteria constitutes the largest proportion. There are anywhere from 500 to 1000 different species of bacteria in the gut population divided into three bacterial phyla: Bacteroidetes (gram-negative), Actinobacteria (gram-positive), and Firmicutes (gram-positive). The Firmicutes consist of over 200 genera which includes Bacillus, Clostridium, Lactobacillus, and Mycoplasma.

Bacteria of the Bacteroidetes phylum constitute up to 30% of the total gut flora. These bacteria are important in the digestion of otherwise non-digestible polysaccharides into monosaccharides and short-chain fatty acids (SCFA) and also may be involved in the synthesis of vitamin K. The bacterial digestion of polysaccharides into SCFA involves a process called saccharolytic fermentation. The primary SCFAs are acetic acid, propionic acid, and butyric acid. SCFAs affect the growth and proliferation of intestinal epithelial cells through a signal transduction process that involves binding to a G-protein coupled receptor identified as GPR41. Following absorption, propionic acid aids the liver in the production of ATP by being converted to propionyl-CoA and then propionyl-CoA is converted to succinyl-CoA followed by oxidation in the TCA cycle. Butryate is used for energy production by intestinal epithelial cells and also has anti-inflammatory properties in the gut. Of significance to the relationship between gut microbiota and obesity, studies have shown that obese individuals had lower levels of Bacteroidetes and more Firmicutes than lean control subjects. When obese patients are placed on either a carbohydrate restricted low calorie diet or a fat restricted diet their ratios of Bacteroidetes to Firmicutes approached those of lean control subjects after several months.

Given that obesity, insulin resistance, and type 2 diabetes are all associated with low-grade systemic inflammation of unclear etiology, it has been proposed that one mechanism leading to this state involves inflammatory modulation by gut bacteria. High-fat diet-induced obesity has been shown to be correlated with the increased expression of several pro-inflammatory cytokines including IL-1, IL-6, MCP-1, and TNF-α. In particular, TNF-α is known to cause insulin resistance, as described above in the NAFLD section (also see Insulin Functions page). Bacterial lipopolysaccharide (LPS) evokes an inflammatory response triggering the secretion of many of these same pro-inflammatory cytokines. LPS is continuously produced by gut bacteria through the lysis of dead and dying gram-negative bacteria. LPS binds to a complex of CD14 and the toll-like receptor 4 (TLR4) on cells of the innate immune system resulting in the secretion of these cytokines. LPS is also transported from the gut to peripheral tissues via interaction with chylomicrons. Since the rate of chylomicron synthesis is elevated in response to a high-fat and/or high-carbohydrate diet, there will be more LPS uptake in obese individuals due to the elevated intake of lipids and carbohydrates. The fat-induced increase in LPS uptake is referred to as metabolic endotoxemia. The role of a high-fat diet in triggering metabolic endotoxemia can be mimicked in the absence of dietary fat by direct infusion of LPS. When these experiments are carried out in mice fed a fat-restricted diet, LPS infusion resulted in fasting hyperglycemia, obesity, steatosis, infiltration of macrophages into adipose tissue, insulin resistance and hyepinsulinemia, the same conditions found in high-fat diet fed mice.

Gut bacteria have also been shown to play a role in the secretion of gastrointestinal hormones that function in digestion and appetite control. One very important gut hormone is glucagon-like peptide-1 (GLP-1). GLP-1 is called an incretin which is a term referring to a substance that promotes pancreatic insulin secretion in response to food intake. For detailed information on GLP-1 see the Gut-Brain Interactions page. The role of GLP-1 in the regulation of digestion, insulin secretion, and appetite is precisely the reason it is a current pharmaceutical target in the treatment of hyperglycemia and type 2 diabetes. GLP-1 is secreted from specialized enteroendocrine cells (L-cells) of the ileum and colon and the composition of the diet affects the release of this hormone. High fat and glucose content stimulate GLP-1 release but proteins do not appear to be involved in its secretion. When animals are fed a high fiber diet composed of non-digestible oligofructose, which can be fermented by gut bacteria, there is an increase in GLP-1 release. Oligofructose is called a prebiotic which is any substance that is non-digestible by humans but can be fermented by gut bacteria thereby promoting their growth and activity. In addition, feeding animals oligofructose results in increased L-cell proliferation in the proximal colon and this contributes to a higher level of GLP-1 release. When rats are fed a high-fat diet which also includes oligofructose there is an improvement in the diabetes induced by the high-fat diet alone. In humans, the consumption of oligofructose protects against weight gain, reduces fat accumulation, reduces serum triglyceride accumulation, and promotes satiety. These effects are presumably due, in part, to changes in the composition of gut microbiota as is seen in experimental animals.

back to the top

Is There a Viral Link to Obesity?

A potential link between obesity and viral infection was initially suggested from studies that demonstrated increased body weight, increased glucose uptake, and decreased leptin secretion in animals infected with adenovirus-36 (Ad-36). Subsequently other viruses such as canine distemper, rous-associated virus 7, scrapie, Borna disease virus, SMAM-1, as well as other adenoviruses were correlated to increasing obesity in animal models. Ad-36 is a virus that primarily infects humans and studies have shown that 30% of obese individuals (compared to only 11% of lean subjects) have circulating antibodies to Ad-36. The precise mechanism by which Ad-36 infection might lead to obesity is unknown. Unlike in animal studies where canine distemper virus and Borna disease virus particles were found in the hypothalamus of obese animals, Ad-36 particles are not found in the hypothalamus of obese human subjects positive for Ad-36 antibodies. However, Ad-36 viral particles have been found in adipocytes and Ad-36 infection increases adipocyte differentiation from pre-adipocytes. It is also possible that adenoviral infection leads to increased inflammatory responses in adipose tissue, and possibly also the liver, that in turn leads to the metabolic disruptions seen to be typical of the pro-inflammatory state associated with, and resulting in, obesity.

Although the current evidence is suggestive of a link between viral infection and obesity the data are not conclusive nor of large enough numbers to clearly demonstrate a causal association to obesity. As more epidemiological data is collected viral infection may indeed be added to the list of known factors in the multifactorial model of the causes of obesity.

back to the top
Return to The Medical Biochemistry Page
Michael W King, PhD | © 1996–2017 themedicalbiochemistrypage.org, LLC | info @ themedicalbiochemistrypage.org

Last modified: May 26, 2017